Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2414 - Breast cancer PAM50 subtypes: correlation between RNA-Seq and multiplexed gene expression platforms

Date

11 Sep 2017

Session

Poster display session

Presenters

Antonio Picornell

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

A.C. Picornell1, I. Echavarria Diaz-Guardamino2, E.L. Alvarez Castillo1, S. Lopez-Tarruella Cobo2, Y. Jerez2, K. Hoadley3, J. Parker3, M. del Monte-Millán2, R. Ramos Medina1, J. Gayarre1, I. Ocaña1, M. Cebollero4, T. Massarrah2, F. Moreno Antón5, J.A. García-Saenz5, H. Gomez Moreno6, A.I. Ballesteros Garcia7, M. Ruíz-Borrego8, C. Perou3, M. Martin Jimenez2

Author affiliations

  • 1 Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), 28007 - Madrid/ES
  • 2 Medical Oncology, Hospital General Universitario Gregorio Marañón, 28007 - Madrid/ES
  • 3 Genetics, University of North Carolina - Chapel Hill, 27599 - Chapel Hill/US
  • 4 Pathology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 5 Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid/ES
  • 6 Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima 34 - Lima/PE
  • 7 Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 8 Oncología, Hospital Virgen del Rocío, Sevilla/ES
More

Resources

Abstract 2414

Background

Gene expression signatures are a key tool for decision-making in breast cancer. In 2000 Perou et al. identified 4 intrinsic subtypes of breast cancer from gene expression data: LumA, LumB, HER2-enriched and Basal-like. These breast cancer subtypes yielded a superior prognostic impact than classical immunohistochemistry factors. From the initial intrinsic subtype, a 50-gene signature was developed for subtype assignment. PAM50 is being successfully used in multiplexed gene expression platforms such as NanoString nCounter®, which is the basis for the Prosigna® test. The latter was approved for the risk of distant relapse estimation in postmenopausal women with hormone receptor+, node+/- early stage breast cancer patients; and is a daily-used tool assessing the need of adjuvant chemotherapy.

Methods

The analyses were performed in paraffin embedded tissues (FFPE) from 96 patients recruited in a multicenter, prospective, non-randomized triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were performed following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both NanoString nCounter® and RNA-Seq technologies. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms.

Results

Subtype calling agreed on 96% of the cases (NanoString nCounter®/RNA-Seq discordances: 3 Basal-like/HER2-enriched and 1 HER2-enriched/LumA). Both the Spearman correlation to each of the centroids and the risk of recurrence (ROR) were above 0.89 in both platforms. Furthermore, the agreement on proliferation score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient >0.80.

Conclusions

The RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it cannot be massively used in the daily clinical practice, due to its processing time requirements and economic costs. We demonstrated that the RNA-Seq technology provides similar results to the NanoString nCounter®, with the latter providing lower cost and more simplicity in its use.

Clinical trial identification

NCT01560663

Legal entity responsible for the study

Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.